Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Non-Current Debt (2021 - 2025)

Indivior Pharmaceuticals has reported Non-Current Debt over the past 5 years, most recently at $290.0 million for Q4 2025.

  • Quarterly results put Non-Current Debt at $290.0 million for Q4 2025, down 7.94% from a year ago — trailing twelve months through Dec 2025 was $290.0 million (down 7.94% YoY), and the annual figure for FY2025 was $290.0 million, down 7.94%.
  • Non-Current Debt for Q4 2025 was $290.0 million at Indivior Pharmaceuticals, down from $304.0 million in the prior quarter.
  • Over the last five years, Non-Current Debt for INDV hit a ceiling of $315.0 million in Q4 2024 and a floor of $237.0 million in Q4 2022.
  • Median Non-Current Debt over the past 5 years was $297.0 million (2025), compared with a mean of $280.1 million.
  • Biggest five-year swings in Non-Current Debt: skyrocketed 32.91% in 2024 and later fell 7.94% in 2025.
  • Indivior Pharmaceuticals' Non-Current Debt stood at $239.0 million in 2021, then decreased by 0.84% to $237.0 million in 2022, then changed by 0.0% to $237.0 million in 2023, then skyrocketed by 32.91% to $315.0 million in 2024, then fell by 7.94% to $290.0 million in 2025.
  • The last three reported values for Non-Current Debt were $290.0 million (Q4 2025), $304.0 million (Q3 2025), and $308.0 million (Q2 2025) per Business Quant data.